CORRESP 1 filename1.htm

 

 

 

August 6, 2020

 

Via EDGAR Transmission

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:BiondVax Pharmaceuticals Ltd.
  Registration Statement on Form F-3
  Filed July 29, 2020
  Registration No. 333-240189

 

Ladies and Gentlemen:

In accordance with Rule 461 of the Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on August 10, 2020 at 4:00 p.m. Eastern Time or as soon thereafter as practicable. Please contact our counsel, Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co., attention: Perry Wildes at +972-3-607-4475, or in his absence, Joshua Ravitz at +972-3-607-4480, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

  Very truly yours,
   
  BiondVax Pharmaceuticals Ltd.
   
  By:  /s/ Uri Ben Or
    Uri Ben Or
Chief Financial Officer

 

 

 

 

 

 

Jerusalem BioPark, 2nd floor ● Hadassah Ein Kerem Campus ● Jerusalem, Israel

Telephone: +972-8-9302529 ● Fax: +972-8-9302531 ● www.BiondVax.com